Skip to content Skip to footer
Subscribe Now
Oncology Top 20 2024
TOP 20

Top 20 Oncology Companies of 2024

Shots: With more than 50 percent of ongoing clinical trials, Oncology remains one of the most explored therapy areas in healthcare In 2023, the global oncology market was valued at $222.36B and is envisioned to grow to $521.6B by 2033, registering a CAGR of 8.9% from 2024 to 2033. With $27.6B registered oncology revenue, Merck…
August 29, 2024

Read more

INSIGHTS+

Disease of the Month – Fabry Disease

Shots:  Fabry disease is a rare inherited neurological disorder that affects the body's ability to break down lipids into smaller components  In this reprise of our Disease of the Month report, we bring an illuminating account of Fabry Disease with deep dive analysis of epidemiology, market size, disease management, available therapies, patient advocacy groups, and…
June 12, 2024

Read more

Disease of the Month – Sjögren’s Syndrome
INSIGHTS+

Disease of the Month – Sjögren’s Syndrome

Shots:  A rare autoimmune condition, Sjögren’s Syndrome is characterized by dry mouth and eye. The condition affects 0.5 to 1% of the global population of which 90% of patients are women  In this reprise of our Disease of the Month report, we bring an illuminating account of Sjögren’s Syndrome with deep dive analysis of epidemiology, market size, disease management, available therapies, patient…
May 16, 2024

Read more

VIEWPOINTS_Meri Beckwith _2024
VIEWPOINTS

Infusing AI in Clinical Trials: Meri Beckwith from Lindus Health in Conversation with PharmaShots

Shots:  Meri Beckwith, Co-Founder of Lindus Health engages in a striking conversation with PharmaShots  Meri talks about bridging the gaps of clinical trials in CNS/Neurology by leveraging LLMs that are trained on nearly a million clinical trial protocols and simple machine learning models to monitor real-time clinical trial data  Meri highlights the importance of multidisciplinary…
May 8, 2024

Read more

Top Performing Drug – Perjeta (January Edition)
INSIGHTS+

Top Performing Drug – Perjeta (January Edition)

Shots:   In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Perjeta and prepared a curated analysis report for our readers  Perjeta is indicated for the treatment of HER2-positive metastatic breast cancer, neoadjuvant HER2-positive breast cancer, Adjuvant HER2-positive breast cancer PharmaShots presents a concise…
January 30, 2024

Read more

ThoughtSpot_Saurabh Chaubey9
THOUGHTSPOT

Targeted Therapy in Oncology

Shots:  The oncology domain accounts for more than 50% of ongoing clinical trials. The global oncology drug market was valued at $185B in 2022 and is predicted to reach $205B by 2030 with a 13% CAGR   Targeted therapy targets specific genes and proteins to prevent them from growing and spreading. In 2022, the market size…
January 3, 2024

Read more

Load more